Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Akari Therapeutics ( (AKTX) ) just unveiled an update.
On March 2, 2026, Akari Therapeutics held a special general meeting of shareholders at which a quorum was present and all resolutions were approved, covering the exercisability and share issuance related to multiple warrant classes tied to recent financings. Shareholders endorsed the potential issuance of ADSs and underlying ordinary shares from Series G, pre-funded, placement agent and note exchange warrants that were issued in registered direct offerings, private placements and note exchanges completed in December 2025 and January 2026, clearing a key Nasdaq compliance hurdle and solidifying the company’s capital-raising arrangements.
The most recent analyst rating on (AKTX) stock is a Hold with a $0.22 price target. To see the full list of analyst forecasts on Akari Therapeutics stock, see the AKTX Stock Forecast page.
Spark’s Take on AKTX Stock
According to Spark, TipRanks’ AI Analyst, AKTX is a Neutral.
The score is pressured primarily by weak financial performance (no revenue, ongoing losses and cash burn) and bearish technicals (price below key moving averages with negative MACD). Corporate events are mixed—financing helps liquidity, but the Nasdaq delisting risk is a significant overhang—while valuation inputs are unavailable, limiting conviction from that component.
To see Spark’s full report on AKTX stock, click here.
More about Akari Therapeutics
Akari Therapeutics is a biopharmaceutical company that issues ordinary shares and American Depositary Shares listed on Nasdaq, using equity and warrant structures to finance its operations. The company regularly accesses the capital markets through registered direct offerings, private placements and note exchanges, reflecting an investor base accustomed to complex securities issuances.
Average Trading Volume: 850,168
Technical Sentiment Signal: Strong Sell
Current Market Cap: $7.7M
See more insights into AKTX stock on TipRanks’ Stock Analysis page.